| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698594 | Clinical Oncology | 2014 | 10 Pages |
Abstract
Results from the prospective ARIES OCS add further evidence to support the effectiveness and safety of bevacizumab when added to first- and second-line treatment regimens for patients with mCRC in community treatment settings.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
H.I. Hurwitz, T.S. Bekaii-Saab, J.C. Bendell, A.L. Cohn, M. Kozloff, N. Roach, Y. Mun, S. Fish, E.D. Flick, A. Grothey, ARIES Study Investigators ARIES Study Investigators,